Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 18Colorectal Neoplasms 17Stomach Neoplasms 10Colonic Neoplasms 7Gastrointestinal Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Recurrence 1Rcctal Cancer 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Gastric Cancer 1Locally Advanced Colorectal Cancer 1Intestinal Neoplasms 1HER2-positive Locally Advanced Resectable Gastric Cancer 1HER2-positive Colorectal Cancer 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Carcinoma 1Adebrelimab (SHR-1316) 1

Interventions

Oxaliplatin 2sintilimab 1irinotecan sucrosofate 1dostarlimab 1XELOX 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Rectal Cancer (LARC) × XELOX × Clear all
NCT07381777 2026-02-02

IMMUNOSTAR

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Not yet recruiting
270 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡